Search

Your search keyword '"Jud, SM"' showing total 118 results
Start Over Author "Jud, SM"
118 results on '"Jud, SM"'

1. Einfluss der Familienanamnese eines Mamma- oder Ovarialkarzinoms auf die pathologische Komplettremission und die Prognose bei Patientinnen mit einem Mammakarzinom nach neoadjuvanter Chemotherapie

Author

Gaß, P, additional, Häberle, L, additional, Hein, A, additional, Jud, SM, additional, Lux, MP, additional, Hack, CC, additional, Emons, J, additional, Heindl, F, additional, Nabieva, N, additional, Loehberg, CR, additional, Schulz-Wendtland, R, additional, Hartmann, A, additional, Beckmann, MW, additional, Fasching, PA, additional, and Wunderle, M, additional

Published
2020
Full Text
View/download PDF

3. Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup

Author

Emons, J, additional, Fasching, PA, additional, Wunderle, M, additional, Heindl, F, additional, Rieger, J, additional, Horn, F, additional, Pelzer, G, additional, Ritter, A, additional, Weber, T, additional, Radicke, M, additional, Polifka, I, additional, Wachter, DL, additional, Wenkel, E, additional, Michel, T, additional, Uder, M, additional, Hartmann, A, additional, Anton, G, additional, Beckmann, MW, additional, Schulz-Wendtland, R, additional, and Jud, SM, additional

Published
2020
Full Text
View/download PDF

6. RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women

Author

Wunderle, M, additional, Rübner, M, additional, Häberle, L, additional, Schwenke, E, additional, Hack, CC, additional, Bayer, CM, additional, Koch, MC, additional, Schwitulla, J, additional, Schulz-Wendtland, R, additional, Kozieradzki, I, additional, Lux, MP, additional, Beckmann, MW, additional, Jud, SM, additional, Penninger, JM, additional, Schneider, MO, additional, and Fasching, PA, additional

Published
2019
Full Text
View/download PDF

7. The diagnostic accuracy of breast medical tactile examiners (MTE) – A first prospective monocentric study

Author

Gaß, P, additional, Emons, J, additional, Bani, MR, additional, Wunderle, M, additional, Sell, C, additional, Preuss, C, additional, Rauh, C, additional, Schrauder, MG, additional, Jud, SM, additional, Hack, CC, additional, Adler, W, additional, Schulz-Wendtland, R, additional, Beckmann, MW, additional, Fasching, PA, additional, and Lux, MP, additional

Published
2018
Full Text
View/download PDF

8. Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe

Author

Emons, J, additional, Wunderle, M, additional, Hartmann, A, additional, Radice, M, additional, Rauh, C, additional, Uder, M, additional, Gass, P, additional, Fasching, PA, additional, Langemann, H, additional, Beckmann, MW, additional, Schulz-Wendtland, R, additional, and Jud, SM, additional

Published
2018
Full Text
View/download PDF

12. Assessment of clinical potential of X-ray dark-field imaging for breast cancer

Author

Emons, J, additional, Wunderle, M, additional, Emons, PA, additional, Heindl, F, additional, Rieger, J, additional, Horn, F, additional, Pelzer, G, additional, Ritter, A, additional, Weber, T, additional, Radicke, M, additional, Polifka, I, additional, Wachter, DL, additional, Wenkel, E, additional, Michel, T, additional, Uder, M, additional, Hartmann, A, additional, Anton, G, additional, Beckmann, MW, additional, Schulz-Wendtland, R, additional, and Jud, SM, additional

Published
2018
Full Text
View/download PDF

14. Optimierung der klinischen Brustuntersuchung durch den Einsatz von medizinischen Tastuntersucherinnen (MTU)

Author

Gaß, P, additional, Emons, J, additional, Schrauder, MG, additional, Bani, MR, additional, Bayer, CM, additional, Sell, C, additional, Strahl, O, additional, Wunderle, M, additional, Hein, A, additional, Jud, SM, additional, Rauh, C, additional, Hack, CC, additional, Schulz-Wendtland, R, additional, Beckmann, MW, additional, and Lux, MP, additional

Published
2017
Full Text
View/download PDF

17. Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast

Author

Sawyer, E, Roylance, R, Petridis, C, Brook, MN, Nowinski, S, Papouli, E, Fletcher, O, Pinder, S, Hanby, A, Kohut, K, Gorman, P, Caneppele, M, Peto, J, Silva, ID, Johnson, N, Swann, R, Dwek, M, Perkins, KA, Gillett, C, Houlston, R, Ross, G, De Ieso, P, Southey, MC, Hopper, JL, Provenzano, E, Apicella, C, Wesseling, J, Cornelissen, S, Keeman, R, Fasching, PA, Jud, SM, Ekici, AB, Beckmann, MW, Kerin, MJ, Marme, F, Schneeweiss, A, Sohn, C, Burwinkel, B, Guenel, P, Laurent-Puig, P, Kerbrat, P, Bojesen, SE, Nordestgaard, BG, Nielsen, SF, Flyger, H, Milne, RL, Perez, JIA, Menendez, P, Benitez, J, Brenner, H, Dieffenbach, AK, Arndt, V, Stegmaier, C, Meindl, A, Lichtner, P, Schmutzler, RK, Lochmann, M, Brauch, H, Fischer, HP, Ko, YD, Nevanlinna, H, Muranen, TA, Aittomaki, K, Blomqvist, C, Bogdanova, NV, Dork, T, Lindblom, A, Margolin, S, Mannermaa, A, Kataja, V, Kosma, VM, Hartikainen, JM, Chenevix-Trench, G, Lambrechts, D, Weltens, C, van Limbergen, E, Hatse, S, Chang-Claude, J, Rudolph, A, Seibold, P, Flesch-Janys, D, Radice, P, Peterlongo, P, Bonanni, B, Volorio, S, Giles, GG, Severi, G, Baglietto, L, McLean, CA, Haiman, CA, Henderson, BE, Schumacher, F, Le Marchand, L, Simard, J, Goldberg, MS, Labreche, F, Dumont, M, Kristensen, V, Winqvist, R, Pylkas, K, Jukkola-Vuorinen, A, Kauppila, S, Andrulis, IL, Knight, JA, Glendon, G, Mulligan, AM, Devillee, P, Tollenaar, RAEM, Seynaeve, Caroline, Kriege, Mieke, Figueroa, J, Chanock, SJ, Sherman, ME, Hooning, Maartje, Hollestelle, Antoinette, van den Ouweland, Ans, van Deurzen, Carolien, Li, JM, Czene, K, Humphreys, K, Cox, A, Cross, SS, Reed, MWR, Shah, M, Jakubowska, A, Lubinski, J, Jaworska-Bieniek, K, Durda, K, Swerdlow, A, Ashworth, A, Orr, N, Schoemaker, M, Couch, FJ, Hallberg, E, Gonzalez-Neira, A, Pita, G, Alonso, MR, Tessier, DC, Vincent, D, Bacot, F, Bolla, MK, Wang, Q (Qing), Dennis, J, Michailidou, K, Dunning, AM, Hall, P, Easton, D, Pharoah, P, Schmidt, Marjanka K, Tomlinson, I, Garcia-Closas, M, Medical Oncology, Clinical Genetics, and Pathology

Subjects
body regions, SDG 3 - Good Health and Well-being, skin and connective tissue diseases
Abstract

Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is generally ER positive (ER+) and often associated with lobular carcinoma in situ (LCIS). Genome-wide association studies have identified more than 70 common polymorphisms that predispose to breast cancer, but these studies included predominantly ductal (IDC) carcinomas. To identify novel common polymorphisms that predispose to ILC and LCIS, we pooled data from 6,023 cases (5,622 ILC, 401 pure LCIS) and 34,271 controls from 36 studies genotyped using the iCOGS chip. Six novel SNPs most strongly associated with ILC/LCIS in the pooled analysis were genotyped in a further 516 lobular cases (482 ILC, 36 LCIS) and 1,467 controls. These analyses identified a lobular-specific SNP at 7q34 (rs11977670, OR (95% CI) for ILC = 1.13 (1.09-1.18), P = 6.0x10(-10); P-het for ILC vs IDC ER+ tumors = 1.8x10(-4)). Of the 75 known breast cancer polymorphisms that were genotyped, 56 were associated with ILC and 15 with LCIS at P

Published
2014

18. Die Verwendung automatisch generierter Texturmerkmale zur Bestimmung der Wahrscheinlichkeit, dass ein mit Ultraschall entdeckter Tumor auf dem Mammogramm übersehen wird

Author

Häberle, L, primary, Hack, CC, additional, Heusinger, K, additional, Wagner, F, additional, Heindl, F, additional, Gaß, P, additional, Jud, SM, additional, Franz, D, additional, Vachon, C, additional, Uder, M, additional, Beckmann, MW, additional, Schulz-Wendtland, R, additional, Wittenberg, T, additional, and Fasching, PA, additional

Published
2016
Full Text
View/download PDF

21. Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases.

Author

Lux, MP, Hildebrandt, T, Knetzger, S-M, Schrauder, MG, Jud, SM, Hein, A, Rauh, C, Fasching, PA, Beckmann, MW, Thiel, FC, Lux, MP, Hildebrandt, T, Knetzger, S-M, Schrauder, MG, Jud, SM, Hein, A, Rauh, C, Fasching, PA, Beckmann, MW, and Thiel, FC

Abstract

BACKGROUND: Medical research studies are becoming increasingly important for optimizing the prevention, diagnosis and treatment of illnesses. Participation in research studies can have many benefits for patients. In randomized and controlled clinical studies, they can receive the best possible medical care currently available. However, only a small proportion of patients nowadays are treated within the framework of medical research. The primary endpoint of this study was to discover what level of knowledge patients have about clinical studies and how they currently perceive them, in order to identify ways of optimizing the information provided about studies from the patients' point of view. METHODS: The study included 2546 patients (breast cancer 21.6%, gynecological cancer 8.3%, obstetrics 32.7%, endometriosis 7.8%, fertility treatment 3.2%, other benign gynecological illnesses 19.2%, no information for 7.2%) in the outpatient clinic (45.2%) and in the in-patient sector (54.8%) at the Department of Gynecology at Erlangen University Hospital and associated centers. In the single-center study, conducted between January 2011 and January 2012, the patients were asked about their level of knowledge regarding the background to medical research studies and the ways in which they are carried out and used. The patients were also asked how they perceived medical studies and how they thought study conditions might be optimized. The three-page questionnaire was included in the feedback sheet received by patients as part of the hospital's quality management system. RESULTS: As a whole, the group only had moderate knowledge about clinical studies. A majority of the respondents considered that studies were valuable (91.6%), but only a few were also willing to take part in them (58.4%). Knowledge and willingness to participate strongly depended on age (P < 0.001), educational level (P < 0.001) and patient group (P < 0.001). Most patients would prefer to decide about participating

Published
2015

23. Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast

Author

Gibson, G, Sawyer, E, Roylance, R, Petridis, C, Brook, MN, Nowinski, S, Papouli, E, Fletcher, O, Pinder, S, Hanby, A, Kohut, K, Gorman, P, Caneppele, M, Peto, J, Silva, IDS, Johnson, N, Swann, R, Dwek, M, Perkins, K-A, Gillett, C, Houlston, R, Ross, G, De Ieso, P, Southey, MC, Hopper, JL, Provenzano, E, Apicella, C, Wesseling, J, Cornelissen, S, Keeman, R, Fasching, PA, Jud, SM, Ekici, AB, Beckmann, MW, Kerin, MJ, Marme, F, Schneeweiss, A, Sohn, C, Burwinkel, B, Guenel, P, Truong, T, Laurent-Puig, P, Kerbrat, P, Bojesen, SE, Nordestgaard, BG, Nielsen, SF, Flyger, H, Milne, RL, Perez, JIA, Menendez, P, Benitez, J, Brenner, H, Dieffenbach, AK, Arndt, V, Stegmaier, C, Meindl, A, Lichtner, P, Schmutzler, RK, Lochmann, M, Brauch, H, Fischer, H-P, Ko, Y-D, Nevanlinna, H, Muranen, TA, Aittomaki, K, Blomqvist, C, Bogdanova, NV, Dork, T, Lindblom, A, Margolin, S, Mannermaa, A, Kataja, V, Kosma, V-M, Hartikainen, JM, Chenevix-Trench, G, Lambrechts, D, Weltens, C, Van Limbergen, E, Hatse, S, Chang-Claude, J, Rudolph, A, Seibold, P, Flesch-Janys, D, Radice, P, Peterlongo, P, Bonanni, B, Volorio, S, Giles, GG, Severi, G, Baglietto, L, Mclean, CA, Haiman, CA, Henderson, BE, Schumacher, F, Le Marchand, L, Simard, J, Goldberg, MS, Labreche, F, Dumont, M, Kristensen, V, Winqvist, R, Pylkas, K, Jukkola-Vuorinen, A, Kauppila, S, Andrulis, IL, Knight, JA, Glendon, G, Mulligan, AM, Devillee, P, Tollenaar, RAEM, Seynaeve, CM, Kriege, M, Figueroa, J, Chanock, SJ, Sherman, ME, Hooning, MJ, Hollestelle, A, van den Ouweland, AMW, van Deurzen, CHM, Li, J, Czene, K, Humphreys, K, Cox, A, Cross, SS, Reed, MWR, Shah, M, Jakubowska, A, Lubinski, J, Jaworska-Bieniek, K, Durda, K, Swerdlow, A, Ashworth, A, Orr, N, Schoemaker, M, Couch, FJ, Hallberg, E, Gonzalez-Neira, A, Pita, G, Alonso, MR, Tessier, DC, Vincent, D, Bacot, F, Bolla, MK, Wang, Q, Dennis, J, Michailidou, K, Dunning, AM, Hall, P, Easton, D, Pharoah, P, Schmidt, MK, Tomlinson, I, Garcia-Closas, M, Gibson, G, Sawyer, E, Roylance, R, Petridis, C, Brook, MN, Nowinski, S, Papouli, E, Fletcher, O, Pinder, S, Hanby, A, Kohut, K, Gorman, P, Caneppele, M, Peto, J, Silva, IDS, Johnson, N, Swann, R, Dwek, M, Perkins, K-A, Gillett, C, Houlston, R, Ross, G, De Ieso, P, Southey, MC, Hopper, JL, Provenzano, E, Apicella, C, Wesseling, J, Cornelissen, S, Keeman, R, Fasching, PA, Jud, SM, Ekici, AB, Beckmann, MW, Kerin, MJ, Marme, F, Schneeweiss, A, Sohn, C, Burwinkel, B, Guenel, P, Truong, T, Laurent-Puig, P, Kerbrat, P, Bojesen, SE, Nordestgaard, BG, Nielsen, SF, Flyger, H, Milne, RL, Perez, JIA, Menendez, P, Benitez, J, Brenner, H, Dieffenbach, AK, Arndt, V, Stegmaier, C, Meindl, A, Lichtner, P, Schmutzler, RK, Lochmann, M, Brauch, H, Fischer, H-P, Ko, Y-D, Nevanlinna, H, Muranen, TA, Aittomaki, K, Blomqvist, C, Bogdanova, NV, Dork, T, Lindblom, A, Margolin, S, Mannermaa, A, Kataja, V, Kosma, V-M, Hartikainen, JM, Chenevix-Trench, G, Lambrechts, D, Weltens, C, Van Limbergen, E, Hatse, S, Chang-Claude, J, Rudolph, A, Seibold, P, Flesch-Janys, D, Radice, P, Peterlongo, P, Bonanni, B, Volorio, S, Giles, GG, Severi, G, Baglietto, L, Mclean, CA, Haiman, CA, Henderson, BE, Schumacher, F, Le Marchand, L, Simard, J, Goldberg, MS, Labreche, F, Dumont, M, Kristensen, V, Winqvist, R, Pylkas, K, Jukkola-Vuorinen, A, Kauppila, S, Andrulis, IL, Knight, JA, Glendon, G, Mulligan, AM, Devillee, P, Tollenaar, RAEM, Seynaeve, CM, Kriege, M, Figueroa, J, Chanock, SJ, Sherman, ME, Hooning, MJ, Hollestelle, A, van den Ouweland, AMW, van Deurzen, CHM, Li, J, Czene, K, Humphreys, K, Cox, A, Cross, SS, Reed, MWR, Shah, M, Jakubowska, A, Lubinski, J, Jaworska-Bieniek, K, Durda, K, Swerdlow, A, Ashworth, A, Orr, N, Schoemaker, M, Couch, FJ, Hallberg, E, Gonzalez-Neira, A, Pita, G, Alonso, MR, Tessier, DC, Vincent, D, Bacot, F, Bolla, MK, Wang, Q, Dennis, J, Michailidou, K, Dunning, AM, Hall, P, Easton, D, Pharoah, P, Schmidt, MK, Tomlinson, I, and Garcia-Closas, M

Abstract

Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is generally ER positive (ER+) and often associated with lobular carcinoma in situ (LCIS). Genome-wide association studies have identified more than 70 common polymorphisms that predispose to breast cancer, but these studies included predominantly ductal (IDC) carcinomas. To identify novel common polymorphisms that predispose to ILC and LCIS, we pooled data from 6,023 cases (5,622 ILC, 401 pure LCIS) and 34,271 controls from 36 studies genotyped using the iCOGS chip. Six novel SNPs most strongly associated with ILC/LCIS in the pooled analysis were genotyped in a further 516 lobular cases (482 ILC, 36 LCIS) and 1,467 controls. These analyses identified a lobular-specific SNP at 7q34 (rs11977670, OR (95%CI) for ILC = 1.13 (1.09-1.18), P = 6.0 × 10(-10); P-het for ILC vs IDC ER+ tumors = 1.8 × 10(-4)). Of the 75 known breast cancer polymorphisms that were genotyped, 56 were associated with ILC and 15 with LCIS at P<0.05. Two SNPs showed significantly stronger associations for ILC than LCIS (rs2981579/10q26/FGFR2, P-het = 0.04 and rs889312/5q11/MAP3K1, P-het = 0.03); and two showed stronger associations for LCIS than ILC (rs6678914/1q32/LGR6, P-het = 0.001 and rs1752911/6q14, P-het = 0.04). In addition, seven of the 75 known loci showed significant differences between ER+ tumors with IDC and ILC histology, three of these showing stronger associations for ILC (rs11249433/1p11, rs2981579/10q26/FGFR2 and rs10995190/10q21/ZNF365) and four associated only with IDC (5p12/rs10941679; rs2588809/14q24/RAD51L1, rs6472903/8q21 and rs1550623/2q31/CDCA7). In conclusion, we have identified one novel lobular breast cancer specific predisposition polymorphism at 7q34, and shown for the first time that common breast cancer polymorphisms predispose to LCIS. We have shown that many of the ER+ breast cancer predisposition loci also predispose to ILC, although there is some heterogeneity between E

Published
2014

24. Therapiepersistenz unter adjuvanter Therapie mit dem Aromataseinhibitor Letrozol bei Patientinnen mit Mammakarzinom

Author

Nabieva, N, primary, Hein, A, additional, Bayer, CM, additional, Burghaus, S, additional, Hack, C, additional, Janni, W, additional, Maass, N, additional, Rody, A, additional, Lux, MP, additional, Loehberg, CR, additional, Heusinger, K, additional, Jud, SM, additional, Rauh, C, additional, Fehm, T, additional, Beckmann, MW, additional, and Fasching, PA, additional

Published
2014
Full Text
View/download PDF

25. Darstellung der Gelenkschmerzen unter Letrozoltherapie anhand von Schmerzlandkarten bei Patientinnen mit Mammakarzinom

Author

Hein, A, primary, Jud, SM, additional, Dammer, U, additional, Bayer, CM, additional, Raabe, E, additional, Rauh, C, additional, Hatko, R, additional, Janni, W, additional, Maass, N, additional, Rody, A, additional, Fehm, T, additional, Beckmann, MW, additional, Lux, MP, additional, Loehberg, CR, additional, Schrauder, MG, additional, and Fasching, PA, additional

Published
2014
Full Text
View/download PDF

26. Messung von Brustvolumenveränderungen in der Schwangerschaft mittels 3D-Volumenmessung im Rahmen der CGATE Studie

Author

Schneider, MO, primary, Bani, MR, additional, Dammer, U, additional, Raabe, E, additional, Haeberle, L, additional, Faschingbauer, F, additional, Schneeberger, S, additional, Renner, SP, additional, Fischer, D, additional, Schulz-Wendtland, R, additional, Fasching, PA, additional, Beckmann, MW, additional, Jud, SM, additional, and Bayer, CM, additional

Published
2014
Full Text
View/download PDF

27. Dreidimensionale Beurteilung der Brustzusammensetzung mit dem Automatisierten Brust Volumen Scanner (ABVS)

Author

Rauh, C, primary, Fasching, PA, additional, Jud, SM, additional, Radicke, M, additional, Linde, I, additional, Wenkel, E, additional, Wittenberg, T, additional, Wagner, F, additional, Zöhrer, F, additional, Georgii, J, additional, Hahn, H, additional, Brehm, B, additional, Uder, M, additional, Beckmann, MW, additional, and Schulz-Wendtland, R, additional

Published
2014
Full Text
View/download PDF

28. Common Breast Cancer Susceptibility Variants in LSP1 and RAD51L1 Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk

Author

Vachon, CM, Scott, CG, Fasching, PA, Hall, P, Tamimi, RM, Li, J, Stone, J, Apicella, C, Odefrey, F, Gierach, GL, Jud, SM, Heusinger, K, Beckmann, MW, Pollan, M, Fernandez-Navarro, P, Gonzalez-Neira, A, Benitez, J, van Gils, CH, Lokate, M, Onland-Moret, NC, Peeters, PHM, Brown, J, Leyland, J, Varghese, JS, Easton, DF, Thompson, DJ, Luben, RN, Warren, RML, Wareham, NJ, Loos, RJF, Khaw, K-T, Ursin, G, Lee, E, Gayther, SA, Ramus, SJ, Eeles, RA, Leach, MO, Kwan-Lim, G, Couch, FJ, Giles, GG, Baglietto, L, Krishnan, K, Southey, MC, Le Marchand, L, Kolonel, LN, Woolcott, C, Maskarinec, G, Haiman, CA, Walker, K, Johnson, N, McCormack, VA, Biong, M, Alnaes, GIG, Gram, IT, Kristensen, VN, Borresen-Dale, A-L, Lindstroem, S, Hankinson, SE, Hunter, DJ, Andrulis, IL, Knight, JA, Boyd, NF, Figuero, JD, Lissowska, J, Wesolowska, E, Peplonska, B, Bukowska, A, Reszka, E, Liu, J, Eriksson, L, Czene, K, Audley, T, Wu, AH, Pankratz, VS, Hopper, JL, dos-Santos-Silva, I, Vachon, CM, Scott, CG, Fasching, PA, Hall, P, Tamimi, RM, Li, J, Stone, J, Apicella, C, Odefrey, F, Gierach, GL, Jud, SM, Heusinger, K, Beckmann, MW, Pollan, M, Fernandez-Navarro, P, Gonzalez-Neira, A, Benitez, J, van Gils, CH, Lokate, M, Onland-Moret, NC, Peeters, PHM, Brown, J, Leyland, J, Varghese, JS, Easton, DF, Thompson, DJ, Luben, RN, Warren, RML, Wareham, NJ, Loos, RJF, Khaw, K-T, Ursin, G, Lee, E, Gayther, SA, Ramus, SJ, Eeles, RA, Leach, MO, Kwan-Lim, G, Couch, FJ, Giles, GG, Baglietto, L, Krishnan, K, Southey, MC, Le Marchand, L, Kolonel, LN, Woolcott, C, Maskarinec, G, Haiman, CA, Walker, K, Johnson, N, McCormack, VA, Biong, M, Alnaes, GIG, Gram, IT, Kristensen, VN, Borresen-Dale, A-L, Lindstroem, S, Hankinson, SE, Hunter, DJ, Andrulis, IL, Knight, JA, Boyd, NF, Figuero, JD, Lissowska, J, Wesolowska, E, Peplonska, B, Bukowska, A, Reszka, E, Liu, J, Eriksson, L, Czene, K, Audley, T, Wu, AH, Pankratz, VS, Hopper, JL, and dos-Santos-Silva, I

Abstract

BACKGROUND: Mammographic density adjusted for age and body mass index (BMI) is a heritable marker of breast cancer susceptibility. Little is known about the biologic mechanisms underlying the association between mammographic density and breast cancer risk. We examined whether common low-penetrance breast cancer susceptibility variants contribute to interindividual differences in mammographic density measures. METHODS: We established an international consortium (DENSNP) of 19 studies from 10 countries, comprising 16,895 Caucasian women, to conduct a pooled cross-sectional analysis of common breast cancer susceptibility variants in 14 independent loci and mammographic density measures. Dense and nondense areas, and percent density, were measured using interactive-thresholding techniques. Mixed linear models were used to assess the association between genetic variants and the square roots of mammographic density measures adjusted for study, age, case status, BMI, and menopausal status. RESULTS: Consistent with their breast cancer associations, the C-allele of rs3817198 in LSP1 was positively associated with both adjusted dense area (P = 0.00005) and adjusted percent density (P = 0.001), whereas the A-allele of rs10483813 in RAD51L1 was inversely associated with adjusted percent density (P = 0.003), but not with adjusted dense area (P = 0.07). CONCLUSION: We identified two common breast cancer susceptibility variants associated with mammographic measures of radiodense tissue in the breast gland. IMPACT: We examined the association of 14 established breast cancer susceptibility loci with mammographic density phenotypes within a large genetic consortium and identified two breast cancer susceptibility variants, LSP1-rs3817198 and RAD51L1-rs10483813, associated with mammographic measures and in the same direction as the breast cancer association.

Published
2012

29. Ist die Betreuung von Frauen mit einem familiären Mammakarzinomrisiko überhaupt finanzierbar? - Gesundheitsökonomische Betrachtung der genetischen Testung, intensivierten Früherkennung und präventiver Maßnahmen aus Sicht des Gesundheitswesens und des Leistungserbringers.

Author

Brunel-Geuder, L, primary, Fasching, PA, additional, Bani, MR, additional, Löhberg, CR, additional, Jud, SM, additional, Schrauder, MG, additional, Wagner, S, additional, Hoyer, J, additional, Reis, A, additional, Wenkel, E, additional, Schulz-Wendtland, R, additional, Beckmann, MW, additional, and Lux, MP, additional

Published
2013
Full Text
View/download PDF

34. Prognostische Relevanz von Ki-67 des Primärtumors in Bezug auf das Gesamtüberleben in der metastasierten Situation beim Mammakarzinom

Author

Löhberg, CR, primary, Almstedt, K, additional, Jud, SM, additional, Häberle, L, additional, Hack, CC, additional, Lux, MP, additional, Thiel, FC, additional, Schrauder, MG, additional, Bayer, CM, additional, Hein, A, additional, Heusinger, K, additional, Heimrich, J, additional, Bani, MR, additional, Renner, S, additional, Beckmann, MW, additional, Hartmann, A, additional, Brunner, M, additional, Wachter, DL, additional, and Fasching, PA, additional

Published
2013
Full Text
View/download PDF

35. Zusammenhang zwischen mammographischer Dichte und dem Proliferationsmarker Ki67 bei Patientinnen mit Mammakarzinom

Author

Jud, SM, primary, Heusinger, K, additional, Rauh, C, additional, Häberle, L, additional, Hein, A, additional, Hack, CC, additional, Meier-Meitinger, M, additional, Lux, MP, additional, Schrauder, MG, additional, Wagner, F, additional, Hartmann, A, additional, Wachter, DL, additional, Hagenbeck, C, additional, Uder, M, additional, Beckmann, MW, additional, Löhberg, CR, additional, Fasching, PA, additional, and Schulz-Wendtland, R, additional

Published
2013
Full Text
View/download PDF

36. Abstract PD07-02: Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results

Author

Fasching, PA, primary, Jud, SM, additional, Hauschild, M, additional, Kümmel, S, additional, Schütte, M, additional, Warm, M, additional, Hanf, V, additional, Muth, M, additional, Baier, M, additional, Schulz-Wendtland, R, additional, Beckmann, MW, additional, and Lux, MP, additional

Published
2012
Full Text
View/download PDF

37. Assoziation der Mammografischen Dichte und dem ER/PgR-Expressionsmuster beim Mammakarzinom.

Author

Glöckner, A, primary, Heusinger, K, additional, Jud, SM, additional, Häberle, L, additional, Hack, C, additional, Meier-Meitinger, M, additional, Lux, MP, additional, Uder, M, additional, Wittenberg, T, additional, Hartmann, A, additional, Schulz-Wendtland, R, additional, Beckmann, MW, additional, Fasching, PA, additional, and Loehberg, CR, additional

Published
2012
Full Text
View/download PDF

42. Mammografische Dichte als Risikofaktor für die Entstehung eines Mammakarzinoms – Ergebnisse einer deutschen Fall-Kontroll-Studie

Author

Zeuner, R, primary, Loehberg, CR, additional, Häberle, L, additional, Jud, SM, additional, Klingsiek, P, additional, Hein, A, additional, Bayer, CM, additional, Rauh, C, additional, Uder, M, additional, Cavallaro, A, additional, May, MS, additional, Adamietz, B, additional, Schulz-Wendtland, R, additional, Wittenberg, T, additional, Wagner, F, additional, Beckmann, MW, additional, Fasching, PA, additional, and Heusinger, K, additional

Published
2011
Full Text
View/download PDF

43. Interesse an einer Bestimmung des individuellen Brustkrebsrisikos und Teilnahmerate an einer chemopräventiven Behandlung in der IBIS II Studie

Author

Hack, C, primary, Löhberg, CR, additional, Häberle, L, additional, Heusinger, K, additional, Dilbat, G, additional, Hein, A, additional, Rauh, C, additional, Rix, NE, additional, Heinrich, S, additional, Buchholz, S, additional, Lex, B, additional, Reichler, B, additional, Adamietz, B, additional, Beckmann, MW, additional, Fasching, PA, additional, Schulz-Wendtland, R, additional, and Jud, SM, additional

Published
2011
Full Text
View/download PDF

49. Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany.

Author

Lux MP, Brendle-Behnisch A, Hack CC, Preuss C, Arkudas A, Horch RE, Beckmann MW, and Jud SM

Abstract

Background/aims: Macromastia can cause physical and psychological problems. Conservative treatments such as physiotherapy and painkillers lead to substantial long-term costs, without any proven medical benefit. In contrast, surgical treatment with reduction mammoplasty leads to improvements in nearly all respects. This study analyzed the costs of reduction mammoplasty and calculated an incremental cost-utility ratio for the treatment., Patients and Methods: The data on 76 patients who underwent reduction mammoplasty between 2008 and 2016 were collected using a two-part questionnaire (preoperative and postoperative) as well as the patients' files. Topics examined besides demographic data included physician visits, medical imaging, integrative medical procedures, remedial procedures, rehabilitation and convalescent measures, drug intake, medical aids, exercise activity, and sick leave days before and after surgery. The data were used to calculate costs per year after surgical treatment for symptomatic macromastia. Costs of surgery, including the process of obtaining insurance reimbursement and postoperative complications, were taken into account to calculate the one-time costs of reduction mammoplasty., Results: The patients' quality of life and satisfaction with the breasts improve after surgery. The one-time costs of reduction mammoplasty per patient amount to EUR 5,885, and the annual costs after surgery are EUR 200. The incremental cost-utility ratio for surgical treatments shows a saving of EUR 380 per quality-adjusted life-year (QALY) gained., Conclusions: These results show that reduction mammoplasty is a treatment that not only improves a patient's quality of life but also saves money in the longer term in comparison with expensive and ineffective conservative treatment for macromastia., Competing Interests: M.P.L., A.B.-B., C.P., A.A., R.E.H., M.W.B., and S.M.J.: no conflicts of interest. C.C.H.: received honoraria from Roche and Novartis., (Copyright © 2021 by S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

50. Mammographic density and prognosis in primary breast cancer patients.

Author

Heindl F, Fasching PA, Hein A, Hack CC, Heusinger K, Gass P, Pöschke P, Stübs FA, Schulz-Wendtland R, Hartmann A, Erber R, Beckmann MW, Meyer J, Häberle L, Jud SM, and Emons J

Subjects
Disease-Free Survival, Female, Humans, Prognosis, Retrospective Studies, Breast Density, Breast Neoplasms diagnostic imaging
Abstract

Purpose: Mammographic density (MD) is one of the strongest risk factors for breast cancer (BC). However, the influence of MD on the BC prognosis is unclear. The objective of this study was therefore to investigate whether percentage MD (PMD) is associated with a difference in disease-free or overall survival in primary BC patients., Methods: A total of 2525 patients with primary, metastasis-free BC were followed up retrospectively for this analysis. For all patients, PMD was evaluated by two readers using a semi-automated method. The association between PMD and prognosis was evaluated using Cox regression models with disease-free survival (DFS) and overall survival (OS) as the outcome, and the following adjustments: age at diagnosis, year of diagnosis, body mass index, tumor stage, grading, lymph node status, hormone receptor and HER2 status., Results: After median observation periods of 9.5 and 10.0 years, no influence of PMD on DFS (p = 0.46, likelihood ratio test (LRT)) or OS (p = 0.22, LRT), respectively, was found. In the initial unadjusted analysis higher PMD was associated with longer DFS and OS. The effect of PMD on DFS and OS disappeared after adjustment for age and was caused by the underlying age effect., Conclusions: Although MD is one of the strongest independent risk factors for BC, in our collective PMD is not associated with disease-free and overall survival in patients with BC., Competing Interests: Declaration of competing interest Peter A. Fasching reports research grants from Novartis and BioNTech and personal fees from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, TEVA, AstraZeneca, Puma, Eisai, Merck Sharp & Dohme, and Myelo Therapeutics. Carolin C. Hack reports personal fees from Roche and Novartis. Julius Emons reports personal fees from Novartis, Pfizer and Eisai. Arndt Hartmann has received honoraria from BMS, MSD, Roche, AstraZeneca, Boehringer Ingelheim, Abbvie, Jansen-Cilag, Diaceutics, Cepheid, Lilly, Agilent, and Ipsen. Ramona Erber has received honoraria from Roche, Eisai, Pfizer, and Novartis and travel grants from BioNTech. The institution of Arndt Hartmann and Ramona Erber conducts research for AstraZeneca, Roche, Janssen-Cilag, NanoString Technologies, Novartis, Cepheid, and BioNTech. All the other authors declare that they have no conflicts of interest., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results